 |
|
 |
 |
 Premium News Article
Pharma-Biotech Sector Hopes Merger & Acquisition Buying Spree Can Cure Financial Pains
SUGAR LAND--June 4, 2008 Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- In addition to developing drugs for the marketplace the old fashioned way, with benefit of labs and scientists, pharma-biotech companies are increasingly turning to cash to pay for mergers and acquisitions that will hopefully fill their pipelines.
Companies featured: AstraZeneca (NYSE:AZN), Schering-Plough (NYSE:SGP), Mylan Laboratories (NYSE:MYL), Merck & Company (NYSE:MRK), Emergent BioSolutions Inc. (NYSE:EBS), Bristol-Myers Squibb Company (NYSE:BMY), Kosan Biosciences Inc. (NASDAQ:KOSN)
Read the Complete Article >>>
Details on this Article:
Industry Segment: Pharmaceutical & Biotech
Word Count: 814 Words
| Login or Register now for instant access! |
 |
Related Articles
Value of Industrial Project Starts in North America at $150 Billion for 200...
 Industrial Info's World Expansion Helps Clients Uncover New Business Opport...
Project Management Excellence Promotes Project Success, by Pathfinder LLC, ...
Weird Science? Big Pharma's Top Three M&A Deals in 2009 Nears $160 Billion
Baltimore's Cel-Sci to Begin Production in $22 Million Aseptic Biopharma Pl...
|
|
|
 |
|
 |
|
|
This article is available for Premium Members only.
Subscribe Now! All Fields are Required...
Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361
All Members Receive the Following Free Resources:
North American Project & Gap Spending
North American Plant Analysis by Industry & Market Region
Market Maps & Stats - Capital & Maintenance Activity
Current & Historic Economic Indicators
30/60/90 Day Weather Forecast
|
© 2010 ALL RIGHTS RESERVED. Industrial Info Resources, Inc. - Sugar Land, TX - 800-762-3361